P042. A phase 2 study of the combination of PLK1 inhibitor, onvansertib, with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer
P044. Switch from prednisone to dexamethasone in patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in a multicenter study
P045. Real-world outcomes with abiraterone plus prednisone or prednisolone in metastatic castration-resistant prostate cancer: The Prostate Cancer Registry
P067. Predictors of resistance to abiraterone acetate (AA) or enzalutamide (ENZ) in patients with metastatic castration resistant prostate cancer (mCRPC) in the post docetaxel setting